Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Asthma exacerbations on benralizumab are largely non-eosinophilic.

Literature DB >> 32767484

Asthma exacerbations on benralizumab are largely non-eosinophilic.

Sophie M Poznanski¹, Manali Mukherjee², Nan Zhao², Chynna Huang², Katherine Radford², Ali A Ashkar¹, Parameswaran Nair².

Abstract

Entities: Chemical

Keywords: airway infections; benralizumab; eosinophils; natural killer cells; severe asthma; sputum

Mesh：

Substances：

Year: 2020 PMID： 32767484 DOI： 10.1111/all.14514

Source DB: PubMed Journal: Allergy ISSN： 0105-4538 Impact factor: 13.146

Keyword Cloud
Cited

× No keyword cloud information.

8 in total

1. Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma.

Authors: Nora Drick; Katrin Milger; Benjamin Seeliger; Jan Fuge; Stephanie Korn; Roland Buhl; Maren Schuhmann; Felix Herth; Benjamin Kendziora; Juergen Behr; Nikolaus Kneidinger; Karl-Christian Bergmann; Christian Taube; Tobias Welte; Hendrik Suhling
Journal: J Asthma Allergy Date: 2020-11-11

2. Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma.

Authors: Ana Gómez-Bastero Fernández; Juan Francisco Medina Gallardo; Julio Delgado Romero; Auxiliadora Romero Falcón; Cristina Benito Bernáldez; Javier Gallego Borrego; Francisco Javier Álvarez-Gutiérrez
Journal: J Asthma Allergy Date: 2022-05-25

Review 3. Interrupting the Conversation: Implications for Crosstalk Between Viral and Bacterial Infections in the Asthmatic Airway.

Authors: Jodie Ackland; Alastair Watson; Tom M A Wilkinson; Karl J Staples
Journal: Front Allergy Date: 2021-10-26

Asthma exacerbations on benralizumab are largely non-eosinophilic.

1. Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma.

2. Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma.

Review 3. Interrupting the Conversation: Implications for Crosstalk Between Viral and Bacterial Infections in the Asthmatic Airway.

4. Reply to: Challenging the paradigm.

Review 5. Biologics in Asthma: A Molecular Perspective to Precision Medicine.

Review 6. How to Choose the Correct Drug in Severe Pediatric Asthma.

Review 7. Eosinophils and Bacteria, the Beginning of a Story.

8. Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity.